Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma.

Ai WZ, Kohrt HE, Timmerman J, Hwang J, Hsu FJ, Czerwinski DD, Taidi B, Levy R.

Am J Hematol. 2011 Jun;86(6):515-8. doi: 10.1002/ajh.22017. Epub 2011 Apr 27. No abstract available.

2.
3.

A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma.

Marcus R, Aultman R, Jost F.

Br J Cancer. 2010 Jan 5;102(1):19-22. doi: 10.1038/sj.bjc.6605443. Epub 2009 Nov 17.

4.

R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.

Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, Di Raimondo F, Carella AM, Pulsoni A, Merli F, Arcaini L, Angrilli F, Stelitano C, Gaidano G, Dell'olio M, Marcheselli L, Franco V, Galimberti S, Sacchi S, Brugiatelli M.

J Clin Oncol. 2013 Apr 20;31(12):1506-13. doi: 10.1200/JCO.2012.45.0866. Epub 2013 Mar 25. Erratum in: J Clin Oncol. 2014 Apr 1;32(10):1095. Dosage error in article text.

PMID:
23530110
5.

Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.

Luminari S, Marcheselli L, Sacchi S, Pozzi S, Bari A, Ilariucci F, Stelitano C, Angrilli F, Lazzaro A, Baldini L.

Cancer. 2009 May 1;115(9):1906-13. doi: 10.1002/cncr.24222.

6.

Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.

Janikova A, Koristek Z, Vinklarkova J, Pavlik T, Sticha M, Navratil M, Kral Z, Vasova I, Mayer J.

Exp Hematol. 2009 Nov;37(11):1266-73. doi: 10.1016/j.exphem.2009.07.011. Epub 2009 Aug 3.

PMID:
19654036
7.

Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma.

Zinzani PL, Stefoni V, Musuraca G, Tani M, Alinari L, Gabriele A, Marchi E, Pileri S, Baccarani M.

Cancer. 2004 May 15;100(10):2190-4.

8.

High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.

Montoto S, Moreno C, Domingo-Doménech E, Estany C, Oriol A, Altés A, Besalduch J, Pedro C, Gardella S, Escoda L, Asensio A, Vivancos P, Galán P, de Sevilla AF, Ribera JM, Briones J, Colomer D, Campo E, Montserrat E, López-Guillermo A; Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB) Spain.

Haematologica. 2008 Feb;93(2):207-14. doi: 10.3324/haematol.11671. Epub 2008 Jan 26.

9.

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P.

Blood. 2005 Feb 15;105(4):1417-23. Epub 2004 Oct 19.

10.

Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas.

Domingo-Domènech E, González-Barca E, Estany C, Sureda A, Besalduch J, Fernández de Sevilla A.

Haematologica. 2002 Nov;87(11):1229-30.

11.

Fatal myelofibrosis following fludarabine administration in a patient with indolent lymphoma.

Palomera L, Azaceta G, Varo MJ, Soria J, Gutierrez M.

Haematologica. 1998 Nov;83(11):1045-6.

12.

Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.

Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA.

J Clin Oncol. 2005 Mar 1;23(7):1500-6. Epub 2005 Jan 4.

PMID:
15632411
13.

Retrospective study of the utility of FLIPI/FLIPI-2 for follicular lymphoma patients treated with R-CHOP.

Numata A, Tomita N, Fujimaki K, Tanaka M, Hashimoto C, Oshima R, Matsumoto K, Matsuura S, Yamamoto W, Motomura S, Ishigatsubo Y.

J Clin Exp Hematop. 2012;52(1):77-9. No abstract available.

14.

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, Wassner-Fritsch E, Stein G.

J Clin Oncol. 2008 Oct 1;26(28):4579-86. doi: 10.1200/JCO.2007.13.5376. Epub 2008 Jul 28.

PMID:
18662969
15.

Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group.

Santini G, Chisesi T, Nati S, Porcellini A, Zoli V, Rizzoli V, Zupo S, Marino G, Rubagotti A, Polacco A, Spriano M, Vimercati R, Congiu AM, Ravetti JL, Aversa S, Candela M, Patti C.

Leuk Lymphoma. 2004 Jun;45(6):1141-7.

PMID:
15359993
16.

Fludarabine versus cyclophosphamide, vincristine, and prednisone in recurrent low-grade lymphomas.

Alliot C.

J Clin Oncol. 2003 Jul 1;21(13):2626; author reply 2626-7. No abstract available.

PMID:
12829689
17.
18.

Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.

Marcheselli L, Bari A, Anastasia A, Botto B, Puccini B, Dondi A, Carella AM, Alvarez I, Chiarenza A, Arcari A, Salvi F, Federico M.

Br J Haematol. 2015 May;169(4):544-51. doi: 10.1111/bjh.13332. Epub 2015 Mar 29.

PMID:
25817296
19.

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Böck HP, Wandt H, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group.

Blood. 2004 Nov 15;104(10):3064-71. Epub 2004 Jul 29.

20.

Current immunochemotherapy strategies in follicular lymphoma.

Giné E, Gutiérrez-García G, López-Guillermo A.

Adv Ther. 2010 Oct;27(10):704-13. doi: 10.1007/s12325-010-0069-7. Epub 2010 Aug 24. Review.

PMID:
20820973

Supplemental Content

Support Center